Abstract
Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions such as inflammation. Since ten years now, it is well known that this enzyme exists under two forms: a constitutive (COX-1) and an inducible form (COX-2). Both enzymes are sensitive to inhibition by conventional nonsteroidal antiinflammatory drugs (NSAIDs). Observations that COX-1, involved in several homeostatic processes, played a housekeeping role while COX-2 expression was associated with inflammation and other pathologies such as cancer proliferation have led to the development of COX-2 selective inhibitors in order to reduce the classical side-effects, of which gastric irritation is the most common, associated with the use of conventional NSAIDs.
Current Medicinal Chemistry
Title: Recent Advances in Inducible Cyclooxygenase (COX-2) Inhibition.
Volume: 7 Issue: 10
Author(s): Xavier de Leval, Jacques Delarge, Fabian Somers, Pascal de Tullio, Yves Henrotin, Bernard Pirotte and Jean-Michel Dogne
Affiliation:
Abstract: Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions such as inflammation. Since ten years now, it is well known that this enzyme exists under two forms: a constitutive (COX-1) and an inducible form (COX-2). Both enzymes are sensitive to inhibition by conventional nonsteroidal antiinflammatory drugs (NSAIDs). Observations that COX-1, involved in several homeostatic processes, played a housekeeping role while COX-2 expression was associated with inflammation and other pathologies such as cancer proliferation have led to the development of COX-2 selective inhibitors in order to reduce the classical side-effects, of which gastric irritation is the most common, associated with the use of conventional NSAIDs.
Export Options
About this article
Cite this article as:
de Leval Xavier, Delarge Jacques, Somers Fabian, de Tullio Pascal, Henrotin Yves, Pirotte Bernard and Dogne Jean-Michel, Recent Advances in Inducible Cyclooxygenase (COX-2) Inhibition., Current Medicinal Chemistry 2000; 7 (10) . https://dx.doi.org/10.2174/0929867003374417
DOI https://dx.doi.org/10.2174/0929867003374417 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Harnessing Pluripotency from Differentiated Cells: A Regenerative Source for Tissue-Specific Stem Cell Therapies
Current Stem Cell Research & Therapy Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry Editorial [ Are Peptide Therapeutics the Future? Guest Editor: Sivaram Pillarisetti ]
Current Pharmaceutical Biotechnology Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Pain and Child: A Translational Hypothesis on the Pathophysiology of a Mild Type-2 Diabetes Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Characteristics of Autoimmune Pancreatitis
Current Pharmaceutical Design Genome-Wide Expression Analysis of Valproate Action: A Systems Level Synthesis
Current Psychopharmacology Synthesis, Evaluation of Analgesic and Gastric Ulcerogenic Activities and the Metabolites in Rat Plasma of Hydantoin Ibuprofen Conjugates
Letters in Drug Design & Discovery A Tropical Lichen, Dirinaria consimilis Selectively Induces Apoptosis in MCF-7 Cells through the Regulation of p53 and Caspase-Cascade Pathway
Anti-Cancer Agents in Medicinal Chemistry CD14 and Toll-Like Receptors: Potential Contribution of Genetic Factors and Mechanisms to Inflammation and Allergy
Current Drug Targets - Inflammation & Allergy Mesenchymal Stem Cell as a Potential Therapeutic for Inflammatory Bowel Disease- Myth or Reality?
Current Stem Cell Research & Therapy Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy Manipulating Kynurenic Acid Levels in the Brain – On the Edge Between Neuroprotection and Cognitive Dysfunction
Current Topics in Medicinal Chemistry Neurolological Disorders and Neuroprotection After Heart Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Exploitable Signaling Pathways for the Treatment of Inflammatory Bowel Disease
Current Signal Transduction Therapy Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Targeting HIV-1 gp41 in Close Proximity to the Membrane Using Antibody and Other Molecules
Current Topics in Medicinal Chemistry Toxic Effects of Aflatoxin B1 on Embryonic Development of Zebrafish (Danio rerio): Potential Activity of Piceatannol Encapsulated Chitosan/poly (Lactic Acid) Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
Current Vascular Pharmacology